key: cord-0306914-3uljxsi0
authors: Lerch, A.; ten Bosch, Q. A.; LAzou Jackson, M.; Bettis, A. A.; Bernuzzi, M.; Murphy, G. A.; Tran, Q. M.; Huber, J. H.; Siraj, A.; Elliot, M.; Hartlage, C.; Koh, K.; Strimbu, K.; Walters, M.; Perkins, A.; Moore, S. M.
title: Projecting vaccine demand and impact for emerging zoonotic pathogens
date: 2021-11-10
journal: nan
DOI: 10.1101/2021.11.09.21266135
sha: f83cc97cef1f0473c22c2532deb9000c70b63658
doc_id: 306914
cord_uid: 3uljxsi0

Despite large outbreaks in humans seeming improbable for a number of zoonotic pathogens, several pose a concern due to their epidemiological characteristics and evolutionary potential. To enable effective responses to these pathogens in the event that they undergo future emergence, the Coalition for Epidemic Preparedness Innovations is advancing the development of vaccines for several pathogens prioritized by the World Health Organization. A major challenge in this pursuit is anticipating demand for a vaccine stockpile to support outbreak response. We developed a modeling framework for outbreak response for emerging zoonoses under three reactive vaccination strategies. Annual vaccine regimen requirements for a population-wide strategy ranged from >670,000 (95% prediction interval: 0-3,630,000) for Lassa virus to 1,190,000 (95% PrI: 0-8,480,000) for Rift Valley fever virus, while the regimens required for ring vaccination or targeting healthcare workers (HCWs) were several orders of magnitude lower. For each pathogen and vaccination strategy, reactive vaccination typically prevented fewer than 10% of cases, because of their presently low R0 values. Targeting HCWs had a higher per-regimen impact than population-wide vaccination. Our framework provides a flexible methodology for estimating vaccine stockpile needs and the geographic distribution of demand under a range of outbreak response scenarios.

Despite large outbreaks in humans seeming improbable for a number of zoonotic pathogens, 26 several pose a concern due to their epidemiological characteristics and evolutionary potential. 27

To enable effective responses to these pathogens in the event that they undergo future 28 emergence, the Coalition for Epidemic Preparedness Innovations is advancing the development 29

of vaccines for several pathogens prioritized by the World Health Organization. A major 30 challenge in this pursuit is anticipating demand for a vaccine stockpile to support outbreak 31 response. We developed a modeling framework for outbreak response for emerging zoonoses 32 under three reactive vaccination strategies. Annual vaccine regimen requirements for a 33 population-wide strategy ranged from >670,000 (95% prediction interval: 0-3,630,000) for Lassa 34 virus to 1,190,000 (95% PrI: 0-8,480,000) for Rift Valley fever virus, while the regimens required 35

for ring vaccination or targeting healthcare workers (HCWs) were several orders of magnitude 36

lower. For each pathogen and vaccination strategy, reactive vaccination typically prevented 37 fewer than 10% of cases, because of their presently low R0 values. Targeting HCWs had a 38 higher per-regimen impact than population-wide vaccination. Our framework provides a flexible 39 methodology for estimating vaccine stockpile needs and the geographic distribution of demand 40 under a range of outbreak response scenarios. human-to-human transmission ensuing from those spillovers are expected to increase the 51 probability that adaptations such as these arise and facilitate more widespread emergence 52 (Morse et al. 2012 ). Because of this evolutionary potential, even zoonotic pathogens with limited 53 human-to-human transmission-as defined by a basic reproduction number, R0, below 1-are 54

viewed as a concern. The status quo of investing in the development of diagnostics, 55 therapeutics, and vaccines only in reaction to emerging disease threats has made the world 56 dangerously vulnerable to pandemics (Røttingen et (MERS-67 CoV), and Nipah virus (NiV). Soon after, it added Rift Valley fever virus (RVFV) and 68 chikungunya virus (CHIKV) to its portfolio. As of early 2021, CEPI was supporting development 69 of a total of 19 different vaccine candidates for these five diseases, in addition to other efforts 70 related to Ebola, COVID-19, and "disease X" (CEPI 2018) . 71

In anticipation of vaccine candidates for these diseases progressing through safety and efficacy 72 trials and towards implementation, there is a need to understand future potential vaccine 73 demand (Røttingen et al. 2017 ). Even though these vaccines are not yet available for public 74 health use, understanding demand at an early stage is important to inform fundraising and 75

planning efforts in support of the manufacturing and distribution infrastructure that will be 76 required for their implementation (Excler et al. 2021 To improve capabilities to plan vaccine stockpiles for emerging zoonotic pathogens, we 85 developed a modeling framework to quantify the vaccine stockpile size needed to meet demand 86 for outbreak response and applied it to LASV, MERS-CoV, NiV, and RVFV ( Figure 1 ). Each of 87 these pathogens is zoonotic, with the majority of human cases believed to result from spillover 88 transmission from non-human hosts accompanied by self-limiting, human-to-human 89 transmission (Linthicum, Britch 

Epidemiological data 136 137

For each of the pathogens, we collated epidemiological data through the end of 2020 from 138 multiple sources, including WHO outbreak reports (e.g., (CSR n.d.)), ProMED reports 139 (https://promedmail.org), country-level reports (https://www.moh.gov.sa, https://ncdc.gov.ng), 140 and a literature search. A detailed overview of the source of epidemiological data for each 141 pathogen can be found in the Supplementary Table S1.  142  143 Spillover simulation 144 Given extensive spatial heterogeneity of incidence, we collated epidemiological data at the first 145 administrative level (adm1) in each country-e.g., province or state-within the study region for 146 each pathogen. The primary epidemiological data used to inform spillover rates was the annual 147

incidence of reported cases of each pathogen at the adm1 level (Table S1 ). Where possible, 148

case data was categorized into cases of documented or suspected human-to-human 149 transmission, documented or suspected spillover cases, and cases of unknown origin. The 150 geographic coverage of our analysis for each pathogen was determined by the geographic 151 distribution of spillover cases in the literature. All countries with at least one documented 152 spillover case were included in our analysis. We excluded countries with imported cases but no 153 spillover from a zoonotic source (e.g., South Korea for MERS-CoV). 154 Spillover rates were estimated using a generalized linear mixed model (GLMM) with a zero-155 inflated negative binomial distribution to capture overdispersion in the annual distribution of 156 spillover cases within an adm1. Spillover cases were defined as documented spillover cases, 157 suspected spillover cases, or cases of unknown origin; thereby excluding any cases of 158 documented or suspected human-to-human transmission. Year, country, and adm1 were 159 treated as random effects, with the adm1 variable nested within the country variable.

Year was 160 also included as a random effect for the zero-inflated portion of the model. Model fitting was 161 conducted using the glmmTMB package in R (Brooks et al. 2017 ). This default model did not 162 converge for NiV; therefore, for NiV we used the GLMM model without the random effect by 163 year in the zero-inflated portion of the model to enable convergence. Then, for each pathogen, 164 we simulated annual spillover cases for each year and adm1 by taking draws (1,000 replicates) 165 from a zero-inflated negative binomial distribution using the estimated parameters from the 166 appropriate GLMM fit. We randomly sampled 1,000 of these simulated spillovers from the last 167 five years as inputs to the outbreak simulation model. 168 169 To account for the seasonality of spillover, we fitted a beta distribution to the timing of spillover 170 cases within a year (daily for MERS, weekly for Lassa fever, monthly for Nipah and RVF) and 171 simulated the timing of each spillover case as a random draw from that distribution (Table 1) . To 172 account for spatial clustering of cases below the adm1 level, we associated each simulated 173 case with a catchment area. We did so according to probabilities proportional to catchment area 174 population. Catchment areas were defined by second administrative level (adm2) or hospitals 175 aggregated within 10 km, which would be consistent with an assumption that cases that seek 176 treatment for the relatively severe symptoms of these diseases do so at larger hospitals. 177

Hospital location data for sub-Saharan Africa used in the analysis of LASV was obtained from 178 (Maina et Outbreak simulation 187 188

To simulate incidence attributable to human-to-human transmission, we considered each 189 spillover case as a potential index case for an outbreak. A schematic overview of both the 190 spillover and outbreak simulation models, including outbreak response, is provided in Figure 2 . 191 Human-to-human transmission was simulated stochastically using a branching process model. Once a vaccination campaign was completed and the delay between vaccination and protective 291 immunity had elapsed, vaccination in the general population removed spillover cases with a 292 probability equal to vaccination coverage in the general population multiplied by per exposure 293 protection (PEP). Vaccination of the general population also removed patient-to-HCW 294 nosocomial cases with probability equal to vaccination coverage in HCWs multiplied by PEP. 295

Vaccination of HCWs had no impact on spillover cases, but it removed nosocomial cases with 296 probability equal to vaccination coverage in HCWs multiplied by PEP. PEP depended on 297 whether a sufficient amount of time since vaccination had elapsed and, in the event of a two-298 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Graphical user interface 319 320

A generalized implementation of the model is provided as a graphical user interface (GUI) at 321 http://eidvaccinedemand.crc.nd.edu. In the generalized implementation, a few adjustments were 322 made to allow for more flexible application of the model and to make computing time more 323 acceptable for an interactive web tool. First, annual spillovers are drawn from a negative 324 binomial distribution and then distributed across the catchment areas with a multinomial 325 distribution proportional to the probability that spillovers occur in these catchment areas. 326

Second, the population in the catchment areas were defined by a negative binomial distribution 327 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2021. ; https://doi.org/10.1101/2021.11.09.21266135 doi: medRxiv preprint so that specific geographies did not need to be reproduced. The default parameters for the GUI 328 of each pathogen were obtained by fitting the corresponding distribution function to the 329 estimated spillover and population data from this study. The source code for the GUI is provided 330 at https://github.com/lerch-a/CEPI_VaccineCampaignGUI. 331 332

Results

Spillover cases and human-to-human transmission 335 336

The median annual number of spillover cases was 6 (95% prediction interval: 0-190) for Nipah, 337

114 (95% PrI: 48-266) for MERS, 185 (95% PrI: 8-13,134) for RVF, and 417 (95% PrI: 142-338 1,837) for Lassa fever ( Figure 3A ). Simulated variability in the annual number of spillover cases 339 matched the cumulative distribution of observed spillover cases for each pathogen (SI Figures 340 S1B-S4B). Spillover rates for each pathogen varied both seasonally (SI Figures S1A-S4A ) and 341 geographically ( Figure 4A ). Spillover cases of Lassa fever were concentrated in Sierra Leone, 342

Liberia, and Nigeria, although a few spillover cases occurred in other western African countries. 343

Spillover of RVF to humans was widespread in South Africa, Madagascar, eastern Africa and 344

the Arabian Peninsula, with frequent spillover cases occurring in several western and northern 345

Africa countries as well. The majority of MERS spillover cases occurred in Saudi Arabia, and the 346 majority of Nipah spillover cases occurred in Bangladesh, with additional spillover events in 347

India and Malaysia. 348 349

The number of cases arising from human-to-human transmission depended on both the 350 spillover rate and R0 ( Figure 3A ). Under our default parameter assumptions, there was no 351 human-to-human RVFV transmission, but in the absence of vaccination the median annual 352 number of human-to-human cases following spillover was 2 (95% PrI: 0-82) for Nipah, 29 (95% 353

PrI: 11-143) for Lassa fever, and 161 (95% PrI: 46-407) for MERS (see Figure 5 for an example 354 of the transmission chains for one catchment area). 355 356

Estimates of vaccine demand 357 358

In our analysis, a median of 0 (95% PrI: 0-8) Nipah reactive vaccination campaigns were 359 triggered annually, compared to 4 (95% PrI: 0-11) MERS campaigns, 5 (95% PrI: 0-20) RVF 360 campaigns, and 0 (95% PrI: 0-20) Lassa fever campaigns ( Figure 3B ). The locations of reactive 361 vaccination campaigns broadly followed the geographic distribution of spillovers for each 362 pathogen, although Lassa fever spillovers in Guinea, Benin, Togo, and western Nigeria were 363 rarely reported frequently enough to trigger a response in our simulations ( Figure 4B ). The 364

number of reactive vaccination campaigns that were triggered, and the timing of those 365 campaigns, was strongly influenced by the seasonal pattern of pathogen spillover (SI Figures 366 S1-S4). 367 368 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2021. ; https://doi.org/10.1101/2021.11.09.21266135 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

For all four pathogens, there was a wide range in the number of vaccine regimens required in a 398

typical year due to the dependence of vaccine demand on the spatiotemporal clustering of 399 spillover cases required to trigger an outbreak response. The largest annual vaccine demand 400 was for RVFV, with a median of 1,191,741 (95% PrI: 0-8,480,275) vaccine regimens required to 401 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2021. ; https://doi.org/10.1101/2021.11.09.21266135 doi: medRxiv preprint target the general population under our baseline outbreak response scenario ( Figure 3C ). The 402 median number of vaccine regimens for MERS-CoV was 870,045 (95% PrI: 0-2,843,407). The 403 median number of vaccine regimens needed for NiV and LASV was zero, implying that an 404 outbreak response was triggered less than 50% of the time. However, the mean number of 405 vaccine regimens was 673,167 (95% PrI: 0-3,629,052) for LASV and 1,450,177 (95% PrI: 0-406 12,240,814) for NiV ( Figure 3C ). The number of vaccine regimens required to conduct a ring 407 vaccination strategy or to cover healthcare workers as a part of an outbreak response was 408

typically several orders of magnitude lower than the number required to cover the general 409 population ( Figure 3C ). The estimated impact of reactive vaccination as an outbreak response tool was generally low for 420 all four pathogens. Vaccinating 70% of the general population in response to an outbreak with a 421 single-dose vaccine prevented an annual median of 43 (95% PrI: 0-5,853) RVF cases, 6 (95% 422

PrI: 0-83) MERS cases, 0 (95% PrI: 0-90) Nipah cases, and 0 (95% PrI: 0-357) cases of Lassa 423 fever ( Figure 3D ). These vaccine impacts correspond to 0.69 (95% PrI: 0-2.92) cases averted 424 per 100,000 vaccine regimens administered for MERS, 3.61 (95% PrI: 0-69.02) for RVF, 0 (95% 425

PrI: 0-9.84) for Lassa fever, and 0 (95% PrI: 0-0.74) for Nipah. Vaccinating only healthcare 426 workers typically had a smaller total impact than vaccinating the general population at the same 427 coverage level, because there was no protection against spillover in the general population, but 428 a larger per-regimen impact due to the lower number of regimens required. Vaccinating 70% of 429

HCWs prevented an annual median of 4 (95% PrI: 0-77) MERS cases, corresponding to 58.9 430 (95% PrI: 0-348.6) cases averted per 100,000 vaccine regimens in HCWs. Vaccinating HCWs 431 averted 0 (95% PrI: 0-46) Lassa fever cases and 0 (95% PrI: 0-48) Nipah cases, corresponding 432 to 0 (95% PrI: 0-710.4) and (95% PrI: 0-303.5) cases averted per 100,000 HCW vaccine 433 regimens respectively (we did not explore vaccinating HCWs against RVFV due to the lack of 434 any documented nosocomial transmission). 435 436

Sensitivity analysis 437 438

The number of total cases increased with higher R 0 values for each pathogen, with the largest 439 sensitivity observed for MERS-CoV, because its higher value of R0 was close to one ( Figure  440 S16). There was also a large increase in the number of vaccine regimens required to vaccinate 441 either the general population or HCWs for MERS-CoV at the higher R0 value, but the impact of 442 R0 on the required number of vaccine regimens was minimal for the other pathogens (Figures 443 S17-S18). As a result, there were minimal differences in the impact of vaccination under higher 444 or lower R0 values for LASV, NiV, or RVFV (Figures S19-S22). Vaccination averted both a 445 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2021. Decreasing the time delay between the outbreak threshold being reached and the start of the 467 vaccination campaign tended to increase the number of cases averted, while increasing the 468 delay reduced the number of cases averted ( Figure 6 ). For MERS-CoV, reducing the time delay 469 from 28 to 7 days increased the median number of cases averted from 6 (95% PrI: 0-83) to 14 470 (95% PrI: 0-112), while increasing the delay to 120 days reduced the number of cases averted 471 to 0 (95% PrI: 0-38). 472 473

Increasing or decreasing the percentage of the population that was targeted during reactive 474 vaccination campaigns also led to corresponding increases or decreases in the number of 475 cases averted ( Figure 6 ). For example, if only 50%, rather than 70%, of the population was 476 vaccinated for MERS-CoV, the median number of cases averted declined from 6 (95% PrI: 0-477 83) to 4 (95% PrI: 0-72). In contrast, if vaccination coverage was increased to 90%, then 7 (95% 478

PrI: 0-93) MERS cases were averted. The number of MERS cases averted per 100,000 vaccine 479 regimens administered decreased from 0.69 (95% PrI: 0-2.92) at 70% coverage, to 0.64 (95% 480

PrI: 0-3.55) at 50% coverage, and 0.63 (95% PrI: 0-2.54) at 90% coverage. The sensitivity of 481 the impact of outbreak response to other campaign parameters considered in our model, 482

including per-exposure protection, time to protection following vaccination, vaccination coverage 483 levels in HCWs, and one-dose vs. two-dose vaccines are provided in Figure 6 . The sensitivity 484

analyses for the other pathogens (NiV, LASV, and RVFV) and for different catchment levels are 485 provided in the Supplement (SI Text). In general, the number of cases averted were highest 486 when the spatial scale for vaccine response (catchment area) was the first administrative level, 487 but the per-regimen vaccination impact was higher for the smaller catchment areas (second 488 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2021. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2021. ; https://doi.org/10.1101/2021.11.09.21266135 doi: medRxiv preprint Model performance 501 502

Our spillover simulation model estimates closely matched the average annual reported number 503 of spillover cases for each pathogen, as well as the observed interannual variability in the 504 number of spillover cases that have occurred in the past few decades. The simulation results 505 also captured the geographic distribution and seasonality of spillover cases for each pathogen. 506

The magnitude, spatial distribution, and timing of spillover rates are the main determinants of 507 how frequently an outbreak response threshold will be triggered and therefore the size of the 508 vaccine stockpile needed for outbreak response. Although these patterns could shift to some 509 degree in the future, our model represents what we know about them presently. In addition to 510

influencing stockpile size, these three factors are also relevant for logistical considerations such 511

as the geographic location(s) of the stockpile and the necessary stockpile replenishment rate 512 (Yen et al. 2015) . 513 514

Stockpile estimates 515 516

The estimated number of vaccine regimens needed to reach vaccination coverage targets in the 517 general population varied considerably across the four pathogens examined. For both LASV 518

and NiV, the median was zero, indicating that reactive vaccination campaigns would not be 519 triggered more than 50% of the time. In contrast, the median numbers of vaccine regimens 520 needed for MERS-CoV and RVFV were 870,000 and 1,190,000, respectively. However, the 521 95% prediction intervals for all four pathogens were wide due to spatial and temporal 522 heterogeneity in spillover rates and overdispersion in outbreak sizes resulting from human-to-523 human transmission. For all four pathogens, the vaccine regimens needed to target HCWs were 524 several orders of magnitude lower than needed to target the general population. 525 526

These results indicate that the size of the vaccine stockpile needed to meet annual reactive 527 vaccination demands will depend on the pathogen's epidemiology, the vaccine coverage 528 strategy, and the specific demands of a sustainable manufacturing strategy. In addition to the 529 median or mean annual vaccine demand, our estimates also provide an estimate of the inter-530 annual variability in vaccine demand and the potential magnitude of vaccine demand in low-531

frequency, but high-demand years. For example, the 75th or 90th percentile of our estimates 532

correspond to the level of demand experienced once every four or ten years, on average. The 533 desired size of a vaccine stockpile will likely depend not only on the average annual vaccine 534

demand, but also on the stockpile capacity needed to adequately handle the unpredictability in 535 the timing, frequency, geography, and magnitude of outbreaks. These questions will depend on 536 sustainable vaccine manufacturing capacity, the geographic distribution of both this 537 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2021. ; manufacturing capacity and the stockpile, and vaccine shelf life. A graphical user interface is 538 available at http://eidvaccinedemand.crc.nd.edu to facilitate interactive exploration of these 539 dependencies. 540 541

Our vaccine demand estimates indicate that the biggest determinant of the size of the reactive 542 vaccine stockpile needs was the vaccination strategy: targeting the general population, only 543

HCWs, or ring vaccination. For pathogens that primarily cause nosocomial outbreaks (e.g., 544

LASV), vaccinating HCWs can protect high-risk individuals. In our analysis, this strategy had a 545 larger impact in terms of cases averted per vaccine regimen than vaccinating the general 546

population. The impact of vaccinating HCWs will be highest when spillovers are highly spatially 547 clustered because vaccination campaigns are more likely to be triggered in high-spillover 548 catchment areas, thereby protecting HCWs against nosocomial transmission in areas where 549 vaccination has already occurred earlier in the transmission season but where the spillover risk 550 may remain high. A ring vaccination strategy would also require significantly fewer regimens 551 than a general vaccination strategy. We estimated that the vaccine demand under a ring 552 vaccination strategy would be similar to the demand under a HCW-vaccination strategy for 553 LASV, NiV, and MERS-CoV, and moderately higher than the HCW-vaccination strategy for 554

RVFV. Another strategy to reduce the number of vaccine regimens needed per reactive 555 campaign that we did not consider in our analysis would be to target high-risk sub-populations 556

instead of the whole population of a catchment area. In the case of RVFV, this would be animal 557 workers like butchers, veterinarians, and farmers who are at highest risk of infection ( outbreak response. Vaccine demand in a given area will be a function of the probability of an 572 outbreak response being triggered and the size of the target population. Because we used a 573 sliding time window for the outbreak threshold, the probability of a reactive vaccination 574

campaign being triggered will also depend on the seasonality of spillover. Spillover cases that 575

are highly seasonal will be more likely to trigger a response than spillovers that occur 576 sporadically throughout the year. Highly seasonal spillover rates also increase the importance of 577 rapid deployment of reactive vaccination campaigns, because the shorter duration of the 578 transmission season increases the likelihood that any delays would cause campaigns to occur 579 only after seasonal spillover transmission has declined. 580 581 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2021. ; https://doi.org/10.1101/2021.11.09.21266135 doi: medRxiv preprint

The size of the outbreak-response catchment areas (our baseline catchment area at the 2nd 582 administrative level vs. 1st administrative units or individual hospitals within each 1st 583 administrative unit) also had a large impact on the frequency and timing of outbreak response. 584

First-level administrative catchment areas triggered more outbreak responses and also have 585 larger population sizes, and would therefore require a larger vaccine stockpile. However, this 586 result assumes that the outbreak threshold (number of cases needed to trigger a reactive 587 vaccination campaign) is the same regardless of the size of the catchment area. Adjusting the 588 threshold size based on the geographic extent or population size of the catchment areas would 589 alter the stockpile requirements and could be one approach to aligning expected stockpile 590 demands with manufacturing capacity. The expected number of regimens needed for adm1 591 catchment areas might also be an overestimate if only certain regions in an adm1 are at risk. 592

Therefore, another approach that could balance the advantage of expanded adm1 catchment 593

surveillance areas against the larger stockpile requirements would be to monitor spillover cases 594 at the adm1 level, but limit reactive vaccination to the adm2 regions within the adm1 catchment 595 area where spillover cases were observed. 596 597

Vaccination impact 598 599

Our results indicate that reactive vaccination strategies for preventing the transmission of 600 zoonotic pathogens with R0<1 tend to have limited impacts. For each of the four pathogens we 601 considered, reactive vaccination of the general population averted fewer than 100 cases per 602

year on average and required more than 10,000 vaccine regimens per case averted. The 603

largest impact (as measured by total cases averted or fraction of cases averted) was achieved 604

for RVFV, which was the only pathogen where >5% of total cases were averted via reactive 605 vaccination under our default assumptions. On a cases-averted per regimen basis, vaccinating 606

HCWs was more effective than vaccinating the general population for each of the pathogens 607 with at least some human-to-human transmission in nosocomial settings (LASV, MERS-CoV, 608

and NiV), suggesting that targeting this group may be a viable strategy for reducing the spread 609 of zoonotic pathogens that are capable of nosocomial transmission. 610 611

Under our baseline reactive vaccination scenario, vaccination averted a higher proportion of 612 RVF cases than cases of the other three diseases, even though we assumed that there was no 613

human-to-human RVFV transmission. The higher impact of reactive vaccination for RVFV was 614 the result of two factors. First, our default threshold to trigger an RVFV vaccination campaign 615 was three cases (compared to 10 cases within a 28-day window for LASV or MERS-CoV), 616 which led to more RVFV campaigns being triggered than for the other diseases. Second, RVFV 617 spillovers are highly clustered in space and time, so additional spillover cases were often 618 concentrated in catchment areas where previous spillovers during the transmission season had 619 already triggered a reactive vaccination campaign. Although the lower threshold led to more 620 vaccine regimens being required for RVFV than for the other pathogens, the per regimen impact 621 of reactive vaccination was still highest for RVFV. These results highlight the importance of 622

understanding the underlying epidemiology of zoonotic pathogens when assessing the 623 feasibility of a reactive vaccination strategy. The spatial and temporal heterogeneity in spillover 624 patterns will be a primary factor determining the potential impact of reactive vaccination for 625 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Delays between the triggering of the outbreak threshold and vaccine administration limit the 651 impact of reactive vaccination. In most simulated outbreaks, the outbreak died out before the 652 vaccination was administered due to the low R0. In light of this, prophylactic immunization of 653

HCWs or people at high risk could have a larger impact than reactive vaccination. However, a 654 potentially important aspect that was not considered in our study was the impact that reactive campaign could be estimated based on the spillover rate, the probability of an outbreak, and the 662 durability of vaccine-derived immunity. 663 664

Limitations 665 666

We have attempted to estimate vaccine stockpile needs and identify the most important 667 determinants of success for reactive vaccination of zoonotic emerging pathogens by modeling 668 several vaccination strategies and exploring the sensitivity of our results to different aspects of 669 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2021. ; https://doi.org/10.1101/2021.11.09.21266135 doi: medRxiv preprint pathogen natural history and vaccine deployment. However, there are some limitations to our 670 approach that could affect these estimates. We briefly mention the main limitations here and 671

include an expanded discussion of these limitations in the SI Text. 672 673

First, there is a relatively poor understanding of the epidemiology of most emerging zoonotic 674 pathogens, and data that could be used to try and elucidate the most important aspects of their 675 epidemiology is limited (Grange et al. 2021) . In this study, we collated epidemiological data and 676

parameter estimates from a variety of published sources and also consulted pathogen-specific 677 experts, but, inevitably, our approach was limited by current knowledge. Second, because the 678 modeling framework is intended to be applicable for a range of emerging zoonotic pathogens, it 679 cannot incorporate all of the specific epidemiological details that might affect vaccine demand or 680 impact for a particular pathogen. Our focus was on the key aspects of epidemiology and 681 outbreak response that influence sustainable manufacturing needs, vaccine stockpile 682 requirements, and the impact of outbreak response. Third, we only considered reported cases 683

when estimating pathogen spillover rates, because undiagnosed or unreported infections would 684 not trigger an outbreak response, which could bias the geographic distribution of vaccine 685 demand away from areas with limited disease surveillance systems. This decision was made to 686 ensure that our framework could be implemented with existing data only, and therefore could be 687 applied to other pathogens in a straightforward manner. 688 689

Fourth, because the extent of community transmission for each of the study pathogens is poorly 690 understood, we assumed that human-to-human transmission was limited to nosocomial 691 settings, which could result in an underestimate of vaccine demand. However, our modeling 692 framework could be used to explicitly represent community transmission dynamics, and for 693 pathogens with R 0 << 1, as was largely the case in this study, the limited size of the modeled 694 transmission chains would be similar in either a community or hospital setting since we did not 695 restrict the potential number of contacts per index case. Fifth, we also assumed that all 696 nosocomial transmission was from patients to HCWs or between HCWs, and that there was no 697 patient-to-patient or HCW-to-patient transmission. Therefore, our estimates of the impact of 698

vaccinating HCWs represents an upper-bound on the effectiveness of this strategy, as 699

instances of patient-to-patient transmission would not be prevented via this strategy. Sixth, 700

another simplifying assumption of our model is that cases in one catchment area do not lead to 701 transmission or an outbreak outside of that catchment area. However, our model already 702

implicitly incorporates the possibility of spread between catchment areas, and although our 703 model does not predict spillover cases occurring outside of each pathogen's currently 704 documented geographic distribution, the reactive vaccination strategies we examined should 705 also be applicable for responding to imported cases and their associated outbreaks. Finally, we 706 did not consider any targeted vaccination strategies beyond ring vaccination or targeting 707 healthcare workers to limit nosocomial outbreaks. 708 709

Conclusion 710 711

To inform the development of sustainable vaccine manufacturing processes for emerging 712 pathogens, we developed a modeling framework to estimate the necessary reactive vaccine 713 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2021. ; https://doi.org/10.1101/2021.11.09.21266135 doi: medRxiv preprint stockpile size for emerging zoonotic pathogens. Our framework provides a flexible methodology 714 for estimating vaccine stockpile needs for outbreak response, and for exploring the impact of 715 epidemiology and vaccination strategies on outcomes that have important logistical implications 716 for sustainable vaccine manufacturing, such as the geographic distribution of demand or the 717 required stockpile replenishment rate. However, our model showed that the impact of reactive 718 vaccination for the four pathogens that we explored was minimal, preventing fewer than 10% of 719 human cases under most scenarios with their current epidemiology. However, all these 720 pathogens are closely monitored for their outbreak potential, and control measures are needed. 721

Targeting populations at higher risk of infection, such as HCWs, had a higher per-regimen 722 impact than population-wide vaccination in outbreak control situations. Our results highlight the 723 need for a more thorough epidemiological understanding of these, and other, emerging zoonotic 724 pathogens. Improved pathogen surveillance and case detection are also essential for improving 725 the model and our estimates of vaccine demand. Further work exploring additional scenarios, 726

such as the possibility of targeting certain high-risk populations or the potential uses of vaccines 727

for outbreak prevention rather than just outbreak response, is also needed to improve the 728 potential impacts of vaccination. 729 730

Acknowledgements 731 732

We thank Jim Robinson of CEPI and several members of the CEPI Scientific Advisory 733 committee for helping formulate the reactive vaccination strategies examined in this manuscript 734 and for providing feedback on our modeling framework. We thank John Edmunds (LASV), 735

Robert Sumaye (RVFV), Bart Haagmans (MERS-CoV), Emily Gurley (NiV), and Steve Luby 736

(NiV) for serving as pathogen-specific experts and providing assistance with identifying key 737 epidemiological features and data gaps for their respective pathogens. We thank Nico Vandaele 738 for feedback on how epidemiological modeling can help inform the planning and development of 739 sustainable vaccine manufacturing. We thank Shweta Bansal and Romain Garnier for 740 discussions regarding the modeling of emerging infectious disease outbreaks and vaccination. 741 742

Funding 743 744

The following authors were supported by a contract from CEPI to the University of Notre Dame: 745 AL, QAtB, QMT, JHH, ASS, ME, CH, KK, KS, MW, TAP, SMM. 746 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 10, 2021. ; https://doi.org/10.1101/2021.11.09.21266135 doi: medRxiv preprint 747  748  Table S1 . Overview of data references. 749 Figure S1 . Spillover and reactive vaccination patterns for Lassa fever virus (LASV). 750 Figure S2 . Spillover and reactive vaccination patterns for Middle Eastern respiratory 751 virus (MERS-CoV). 752 Figure S3 . Spillover and reactive vaccination patterns for Nipah virus (NiV). 753 Figure S4 . . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 10, 2021. ; https://doi.org/10.1101/2021.11.09.21266135 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 10, 2021. ; https://doi.org/10.1101/2021.11.09.21266135 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Average weekly number of reactive campaigns triggered via spillover detection. Fitted 1267 seasonality is not shown for RVFV as it was for the other pathogens because seasonality was fit 1268 separately for each region. 1269 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In addition to our baseline reactive vaccination scenario, we examined the sensitivity of 1274 vaccination impact to varying different scenario parameters: the threshold number of cases 1275 needed to trigger a response, vaccination coverage in the general population, vaccination 1276 coverage of healthcare workers (HCWs), time from the threshold trigger to the start of 1277 vaccination, vaccine per exposure protection for one or two doses (PEP), and time delay from 1278 vaccination to protection (see Table 2 for default, low, and high parameter values). In addition, 1279

we examined the sensitivity of model results to the assumed or estimated value of R0 for each 1280 pathogen (SI Text section 2), and the impact of defining different catchment areas for 1281 vaccination (SI Text section 3). The results of the sensitivity analysis for MERS-CoV are 1282 summarized in the main text ( Figure 6 ). 1283 1284

As expected, lowering the number of cases required to trigger a reactive vaccination campaign 1285 or increasing the percent of the population targeted for vaccination increased the number of 1286 vaccine regimens required for each pathogen (Figures S5-S8 ). These parameter values had a 1287 similar impact on the number of vaccine regimens needed to vaccinate HCWs ( Figures S9-1288 S12). Higher R0 values also increased the required number of vaccine regimens needed as 1289

higher human-to-human transmission increased the likelihood of the case threshold being 1290 exceeded. However, this impact was fairly small for LASV and RVFV due to their low R0 values 1291

( Figures S5,S8 ). 1292 1293

When vaccination impact was measured as the fraction of cases averted, the largest impact for 1294 each pathogen was achieved by lowering the threshold number of cases needed to trigger a 1295 reactive vaccination campaign ( Figures 4A, S13A-15A) . The second largest impact on the 1296 fraction of cases averted for each pathogen besides RVFV was achieved by decreasing the 1297 delay between a campaign being triggered and the start of vaccination (Figures 4A, S13A-1298 S14A). For RVFV, the 2nd largest fraction of cases could be averted by increasing vaccination 1299 coverage in the general population or increasing vaccine PEP for a single dose vaccine ( Figure  1300 S15A). Although lowering the response threshold maximized the fraction of cases averted for 1301 each pathogen, it did not maximize the number of cases averted per vaccine regimen 1302 administered, because lowering the threshold increased the number of vaccine campaigns and 1303 the required number of vaccine regimens ( Figures S5-S8 , 4B, S13B-S15B). For LASV, the 1304 largest per regimen impact was achieved by minimizing the delay prior to vaccination ( Figure  1305 S13B). For NiV and RVFV, the largest per regimen impact was achieved by raising the 1306 response threshold (Figures S14B-S15B) . 1307 1308

For each pathogen (besides RVFV, which is not associated with nosocomial transmission) 1309

vaccinating HCWs had a larger per regimen impact than vaccinating the general population 1310

( Figures 4C, S13C-S14C ). Reducing the delay prior to vaccination and increasing vaccine PEP 1311 had the largest impact on the number of cases averted per HCW vaccinated (Figures 4C, S13C-1312 S14C). The number of cases averted was slightly lower under our high-coverage of HCWs 1313 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2021. ; https://doi.org/10.1101/2021.11.09.21266135 doi: medRxiv preprint scenario because the high coverage of vaccination among HCWs was paired with low coverage 1314 among the general population (Figures 4A, S13A-S15A). However, this scenario would have 1315 achieved the highest number of cases averted per total number of vaccine regimens 1316 administered for LASV, MERS-CoV, and NiV. 1317 1318 2. Sensitivity analysis: Impact of R0 1319 1320

All R0 values and uncertainty ranges used in our analysis were either drawn from the literature 1321 or estimated from data (see Table 1 for parameter values and data sources). However, R0 1322 estimates vary between studies and can also vary in space or time due to different 1323 environmental conditions or differences in human contact networks. Therefore, we also tested 1324

the sensitivity of our model results to lower and higher R0 values for each pathogen (for RVFV, 1325 the default R0=0, so only sensitivity to a higher value was examined). The number of total cases 1326 increased with R0 for each pathogen, with the largest sensitivity observed for MERS-CoV 1327 because the high estimate of R0 was close to 1 ( Figure S16 ). There was also a large increase in 1328 the number of vaccine regimens required to vaccinate either the general population or HCWs for 1329

MERS-CoV at the higher R0 value, but the impact of R0 on the required number of vaccine 1330 regimens was minimal for the other pathogens (Figures S17-S18). As a result, there were 1331 minimal differences in the impact of vaccination under higher or lower R0 values for LASV, NiV, 1332

or RVFV (Figures S19-S22) . Vaccination averted both a greater magnitude and a higher fraction 1333 of MERS cases as R0 increased (Figures S19-S20 ). In addition, the number of MERS cases 1334 averted per vaccine regimen administered to the general population or to HCWs also increased 1335 as R0 increased (Figures S21-S22) . These results highlight the increasing potential 1336 effectiveness for reactive vaccination as a control strategy as R0 approaches 1 and larger 1337 outbreaks become more likely. 1338 1339

3. Model limitations 1340 1341

The goal of our analysis was to estimate vaccine stockpile needs and identify the most 1342 important determinants of success for reactive vaccination of zoonotic emerging pathogens. We 1343 modeled several different reactive vaccination strategies that are applicable to any zoonotic 1344 emerging pathogen, and tested this framework for four pathogens with differing epidemiologies. 1345

In addition, we explored the sensitivity of our results to different aspects of reactive vaccine 1346 deployment, such as the coverage level, deployment delays, and vaccine per exposure 1347 protection. However, there are some limitations to our approach that could affect these 1348 estimates. 1349 1350

First, we have a relatively poor understanding of the epidemiology of most emerging zoonotic 1351 pathogens, and data that could be used to try and elucidate the most important aspects of their 1352 epidemiologies is limited. Here we examined the impact of reactive vaccination for four 1353 pathogens with differing epidemiologies to try and capture how a range of epidemiological 1354

parameters (e.g., spillover rates, R0, etc.) affect vaccine stockpile requirements and the likely 1355 impact of vaccination. But there are still uncertainties surrounding the epidemiology of these 1356 pathogens that could affect the results of our analysis, such as the frequency of human-to-1357 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In addition, because no vaccines have been licensed for these 1360 pathogens yet, we had to make assumptions about key vaccine parameters (e.g., number of 1361 doses, time between vaccination and protection, and per exposure protection), based on the 1362 current vaccine target product profiles (TPPs) for each pathogen. We also had to make 1363 assumptions about the baseline reactive vaccination campaign parameter estimates such as 1364 campaign response time and duration (and best-case and worst-case scenarios for our 1365 sensitivity analysis). Assessing vaccine stockpile needs for newly emerged pathogens will 1366

involve even more uncertainty as epidemiological knowledge is critically limited immediately 1367

following emergence, as was demonstrated following the 2019 emergence of SARS-CoV-2 ( (Figures S1-S4) . We 1397 also assumed that all nosocomial transmission involved transmission from patient to HCWs or 1398 between HCWs and that there was no patient-to-patient or HCW-to-patient transmission. 1399

Therefore our estimates of the impact of vaccinating HCWs represents the upper-bound on the 1400 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Another limitation is that we had to make several simplifying assumptions regarding the 1422 implementation of the reactive vaccination campaigns. One such simplification was assuming 1423 that all vaccine doses (per regimen) were administered on the same day. This is likely an 1424

unrealistic assumption for mass vaccination campaigns, particularly those that cover large 1425 geographic areas. Relaxing this assumption would reduce the public health impact of reactive 1426 vaccination in the same manner that delays in the start of the vaccination campaign did in our 1427

analysis. Another simplification is that we did not consider any targeted vaccination strategies 1428 besides targeting healthcare workers to limit nosocomial outbreaks or ring vaccination around 1429 index cases. For the ring vaccination we calculated the number of index cases that would trigger 1430 a ring vaccination response, but we did not model the impact of this response. Besides these 1431 two strategies, there might be other targeted vaccination approaches that would require a 1432 smaller vaccine stockpile than targeting the general population while still producing a substantial 1433 public health impact. For example, in the case of RVFV, a potential vaccination strategy might 1434 include targeting high-risk groups such as veterinarians, butchers, and livestock holders. One 1435 reason we did not consider this strategy is because of the coarseness or absence of the data 1436 available on these professions. While veterinarians only constitute a small proportion of the at-1437 risk population, their higher risk of acquiring infections could increase the impact of a campaign 1438 that targeted them for vaccination. This could also increase the safety of those that are often at 1439 the frontline of an outbreak response. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. See Table 2 for specific parameter values.  1458  1459  1460 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The impact of varying several model parameters on the number of vaccine regimens required to 1463 meet reactive vaccination campaign targets. Base refers to the default scenario used in our 1464 main analysis. See Table 2 for specific parameter values. 1465 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 2 for  1470 specific parameter values. 1471 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. See Table 2 for specific parameter values. 1476 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Base refers to the default scenario used in our main analysis. See Table 2 for specific  1493 parameter values. 1494 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Base refers to the default scenario used in our main analysis. See Table 2 for specific  1499 parameter values. 1500 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2021. ; https://doi.org/10.1101/2021.11.09.21266135 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2021. ; https://doi.org/10.1101/2021.11.09.21266135 doi: medRxiv preprint impact was relatively consistent across different catchment areas, and for Nipah the median 1625 impact per 100,000 vaccine regimens administered was 0 for adm2 or adm1 hospital catchment 1626 areas and 0.01 (95% PrI: 0-11.17) for adm1 catchment areas. For MERS and Lassa fever, the 1627 largest impact of vaccinating HCWs as measured on a per-regimen-administered basis, was 1628 also achieved using adm1 hospital catchment areas. The per-regimen impact of vaccinating 1629

HCWs was minimal for Nipah, just as it was for vaccinating the general population (although the 1630 estimated per-regimen impact of vaccinating HCWs was higher than the impact of vaccinating 1631 the general population). 1632 1633 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Average weekly number of reactive campaigns triggered via spillover detection compared to the 1640 estimated seasonal spillover rate (red line). 1641 1642 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. spillover detection compared to the estimated seasonal spillover rate (red line). 1667 1668 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2021. ; https://doi.org/10.1101/2021.11.09.21266135 doi: medRxiv preprint . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 10, 2021. ; https://doi.org/10.1101/2021.11.09.21266135 doi: medRxiv preprint

More Deaths from Rift Valley Fever in Saudi Arabia and Yemen

Containing a Lassa Fever Epidemic in a Resource-Limited Setting: 765 Outbreak Description and Lessons Learned from Abakaliki

The Risk of Nosocomial Transmission of Rift Valley Fever

Prevalence and Risk Factors of Lassa Seropositivity in Inhabitants of the Forest 966 Region of Guinea: A Cross-Sectional Study

New 969 Opportunities for Field Research on the Pathogenesis and Treatment of Lassa Fever

MERS Outbreak in Korea: Hospital-to-Hospital Transmission

Laboratory Infections with the Virus of Rift Valley Fever 1

The Role of Superspreading in Middle East 976 Respiratory Syndrome Coronavirus (MERS-CoV) Transmission

Infections among 981 Contacts of Patients with Nipah Virus, India

Epidemic Rift Valley Fever in Egypt: Observations of the Spectrum of 985 Human Illness

The Engines of SARS-CoV-2 Spread

Rift Valley Fever: An 990 Emerging Mosquito-Borne Disease

Using Modelling to Disentangle the Relative Contributions of 993 Zoonotic and Anthroponotic Transmission: The Case of Lassa Fever

Recurrent Zoonotic Transmission of Nipah 997 Virus into Humans

A Spatial 1001 Database of Health Facilities Managed by the Public Health Sector in Sub Saharan 1002 Africa

A 1004 Prospective Study of the Epidemiology and Ecology of Lassa Fever

Optimizing Influenza Vaccine Distribution

The Epidemiology 1012 of Rift Valley Fever in Mayotte: Insights and Perspectives from 11 Years of Data

Short Communication: Lassa Fever in Sierra Leone: UN Peacekeepers Are at 1016 Risk

Lassa Fever and Marburg Virus Disease

A Hospital Epidemic of Lassa Fever in Zorzor

2012. 1026 "Prediction and Prevention of the next Pandemic Zoonosis

Rift Valley Fever Virus Exposure 1030 amongst Farmers, Farm Workers, and Veterinary Professionals in Central South Africa

Presence of Middle East Respiratory 1034 Syndrome Coronavirus Antibodies in Saudi Arabia: A Nationwide, Cross-Sectional

The Lancet Infectious Diseases

Rift Valley Fever; I. The Occurrence of Human Cases in 1038 Johannesburg

Low-Level Middle East Respiratory Syndrome 1042 Coronavirus among Camel Handlers

Mapping the Zoonotic Niche of Lassa Fever in Africa

Sequential Rift Valley Fever Outbreaks in 1050 Eastern Africa Caused by Multiple Lineages of the Virus

Transmission of Nipah Virus -14 Years of Investigations in Bangladesh

Transmission of Nipah Virus -14 Years of Investigations in 1060 Bangladesh

Prevalence and Risk Factors 1067 of Rift Valley Fever in Humans and Animals from Kabale District in Southwestern 1068

Serosurveillance of Viral Pathogens Circulating in West Africa

Public Health Response 1075 to Two Imported, Epidemiologically Related Cases of Lassa Fever in the Netherlands 1076

Case-Control Study of Risk Factors for Human Infection with a New 1081 Zoonotic Paramyxovirus, Nipah Virus, during a 1998-1999 Outbreak of Severe 1082 Encephalitis in Malaysia

Outbreaks of Middle East Respiratory Syndrome in 1085 Two Hospitals Initiated by a Single Patient in Daejeon, South Korea

Rift 1088 Valley Fever Virus(Bunyaviridae: Phlebovirus): An Update on Pathogenesis, Molecular 1089 Epidemiology, Vectors, Diagnostics and Prevention

Epidemic in the Middle East and Risk of International Spread Using a Novel Maximum 1093 Likelihood Analysis Approach

ProMED-Mail

Agricultural Intensification, 1099 Priming for Persistence and the Emergence of Nipah Virus: A Lethal Bat

Mohammad Jahangir Hossain, Sharmin Sultana, Nusrat Homaira

Date Palm Sap 1103 Linked to Nipah Virus Outbreak in Bangladesh

Rift Valley Fever in Egypt and Other African Countries: Historical Review, Recent Outbreaks 1109 and Possibility of Disease Occurrence in Egypt

Nigeria Hit by Unprecedented Lassa Fever Outbreak

New Vaccines against Epidemic Infectious Diseases

Target Product Profiles for Rift Valley Fever Virus Vaccines

Rift Valley Fever in 1180 Rural Northern Senegal: Human Risk Factors and Potential Vectors

An Outbreak of Rift Valley Fever in Northeastern 1184

The Development of Global Vaccine Stockpiles

Nipah Virus Infection in Bats (Order Chiroptera) in Peninsular Malaysia

Rift Valley Fever Outbreak

Ministry of Health -Kingdom of Saudi Arabia" 2020)

Rift Valley Fever in Egypt and Other African 1216 Countries: Historical Review, Recent Outbreaks and Possibility of Disease Occurrence in

WHO | Rift Valley Fever -Gambia

Centers for Disease Control 1221 and Prevention (CDC) 2020), 37 (FAO 2017)

Disease Control and Prevention (CDC) 1998)

Analysis of different spillover and vaccination catchment areas baseline adm2 catchment areas, although the frequency of years with no campaigns was 1581 slightly higher for the adm1 hospital

95% PrI: 1,416,969) for adm1 1588 catchment areas. For LASV, the median required number of regimens increased from 0 (95% 1589 PrI: 0-4,452,966) for adm1 hospital catchment areas and 0 (95% PrI: 0-5,184,360) for adm2 1590 catchment areas

For Lassa fever, the median number of cases averted 1600 increased from 0 (95% PrI: 0-306) for adm1 hospital catchment areas and 0 (95% PrI: 0-357) for 1601 adm2 catchment areas, to 101 (95% PrI: 3-771) for adm1 catchment areas. For RVF, the 1602 median number of cases averted increased from 29 (95% PrI: 0-3,525) for adm1 hospital 1603 catchment areas, to 43 (95% PrI: 0-5,826) for adm2 catchment areas, and 66 (95% PrI: 0-1604 2,451) for adm1 catchment areas. For Nipah, the median number of cases averted was 0 for 1605 each catchment area definition, but the mean was highest for adm1 catchment areas. The total 1606 number of cases averted via vaccination of HCWs was also lowest using adm1 hospital 1607 catchment areas and highest using adm1 catchment areas (Figures 1D, S33D-S34D). For 1608 example, for MERS, the median number of nosocomial cases averted increased from 1 (95% 1609 PrI: 0-60) for adm1 hospital catchment areas, to 4 (95% PrI: 0-77) for adm2 catchment areas, 1610 and 55 (95% PrI: 0-259) for adm1 catchment areas. 1611 1612 Although the number of cases averted via reactive vaccination was highest using adm1 1613 catchment areas, the number of cases averted per vaccine regimen administered was not 1614 necessarily the highest under this scenario because the number of regimens required was also 1615 higher using adm1 catchment areas. For MERS, the highest per regimen impact was achieved 1616 using adm1 hospital catchment areas where a median of 0.75 (95% PrI: 0-18.10) cases were 1617 averted per 100,000 vaccine regimens administered

areas are larger than the adm2 catchment areas, while the adm1 hospitals catchment areas are 1553 generally smaller than the adm2 catchment areas. Because spillover rates were estimated at 1554 the adm1 level, spillovers within an adm1 unit were allocated via a multinomial distribution to all 1555 hospital catchment areas within that adm1 unit, with a probability of 1/(# of catchment areas 1556 within adm1). 1557 1558The number of spillover cases remained the same under the different catchment area 1559definitions, but the frequency, timing, and location of reactive vaccination campaigns were 1560shifted. Reactive vaccination campaigns tended to be triggered sooner during the transmission 1561 season for adm1 catchment areas because these catchment areas covered a broader area and 1562 larger population (Figures S23-S26 ). There were only minor differences in the timing of 1563 vaccination campaigns between the adm2 and adm1 hospitals catchment areas ( Figures S1-S4 The total number of human-to-human cases did not differ by catchment area definition for any of 1571 the pathogens (Figures 1A, S33A-S34A ). The median number of reactive vaccination 1572 campaigns was lower using adm1 catchment areas than adm2 catchment areas for MERS-CoV 1573(3; 95% PrI: 1-6 vs. 4; 95% PrI: 0-11) and RVFV (3; 95% PrI:0-6 vs. 5; 95% PrI: 0-20) (Figures  1574  1B, S33B ). In contrast, the median number of reactive vaccination campaigns were higher using 1575 adm1 catchment areas for LASV (3; 95% PrI: 1-6 vs. 0; 95% PrI: 0-20) and NiV (1; 95% PrI: 0-3 1576 vs. 0; 95% PrI: 0-8). The frequency of years with no reactive vaccination campaigns was lower 1577 using adm1 catchment areas compared to adm2 or adm1 hospital catchment areas for all four 1578pathogens. Both the median number of reactive vaccination campaigns and the frequency of 1579 years with no campaigns were similar using adm1 hospital catchment areas compared to the 1580